UY27863A1 - Nueva combinacion - Google Patents

Nueva combinacion

Info

Publication number
UY27863A1
UY27863A1 UY27863A UY27863A UY27863A1 UY 27863 A1 UY27863 A1 UY 27863A1 UY 27863 A UY27863 A UY 27863A UY 27863 A UY27863 A UY 27863A UY 27863 A1 UY27863 A1 UY 27863A1
Authority
UY
Uruguay
Prior art keywords
new combination
cmpc
pde5
angiotensin
hypertension
Prior art date
Application number
UY27863A
Other languages
English (en)
Spanish (es)
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY27863A1 publication Critical patent/UY27863A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY27863A 2002-06-26 2003-06-24 Nueva combinacion UY27863A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0214784.1A GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination

Publications (1)

Publication Number Publication Date
UY27863A1 true UY27863A1 (es) 2003-12-31

Family

ID=9939342

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27863A UY27863A1 (es) 2002-06-26 2003-06-24 Nueva combinacion

Country Status (20)

Country Link
EP (1) EP1524996A2 (https=)
JP (1) JP2005531627A (https=)
KR (1) KR20050013156A (https=)
CN (1) CN1662257A (https=)
AR (1) AR040337A1 (https=)
AU (1) AU2003242895A1 (https=)
BR (1) BR0312030A (https=)
CA (1) CA2491002A1 (https=)
GB (1) GB0214784D0 (https=)
GT (1) GT200300124A (https=)
MX (1) MXPA04012569A (https=)
NO (1) NO20050400L (https=)
PA (1) PA8575501A1 (https=)
PE (1) PE20040868A1 (https=)
PL (1) PL375079A1 (https=)
RU (1) RU2004136276A (https=)
TW (1) TW200404546A (https=)
UY (1) UY27863A1 (https=)
WO (1) WO2004002461A2 (https=)
ZA (1) ZA200409532B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
EP2433555A3 (en) * 2002-07-26 2013-01-16 Olympus Corporation Image processing system
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0502411A (pt) * 2005-03-31 2006-11-28 Univ Minas Gerais processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
ES2376628T3 (es) 2005-06-10 2012-03-15 Dong-A Pharmaceutical Co., Ltd. Agente para la prevención y el tratamiento de las enfermedades hep�?ticas que contiene un dirivado pirazolopirimidina.
WO2007010337A2 (de) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben
EP1940389A2 (en) * 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
AU2007249399A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
RU2345763C1 (ru) * 2007-04-26 2009-02-10 ФГУ "Московский научно-исследовательский институт психиатрии Федерального агентства по здравоохранению и социальному развитию" Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6362178B1 (en) * 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AP2002002455A0 (en) * 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
WO2002013798A2 (en) * 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Also Published As

Publication number Publication date
ZA200409532B (en) 2006-06-28
CN1662257A (zh) 2005-08-31
PE20040868A1 (es) 2004-11-25
MXPA04012569A (es) 2005-04-19
AU2003242895A1 (en) 2004-01-19
RU2004136276A (ru) 2005-09-10
KR20050013156A (ko) 2005-02-02
JP2005531627A (ja) 2005-10-20
BR0312030A (pt) 2005-03-22
AR040337A1 (es) 2005-03-30
GT200300124A (es) 2004-03-17
NO20050400L (no) 2005-03-29
WO2004002461A3 (en) 2004-05-13
GB0214784D0 (en) 2002-08-07
EP1524996A2 (en) 2005-04-27
PL375079A1 (en) 2005-11-14
PA8575501A1 (es) 2003-12-30
WO2004002461A2 (en) 2004-01-08
TW200404546A (en) 2004-04-01
CA2491002A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
DK1097711T3 (da) Behandling af pulmonal hypertension
ATE387446T1 (de) Pyrido(2,3-d)pyrimidin-2,4-diamine als pde-2- inhibitoren
CL2012002380A1 (es) Compuestos derivados de bezoimidazol, inhibidores de mek; utiles en el tratamiento del cancer.(divisional solicitud cl 521-03)
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
LTPA2013018I1 (lt) 4-oksochinolino junginiai ir jų, kaip živ inregrazės inhibitorių, panaudojimas
NL1024643A1 (nl) Purineverbindingen en gebruik daarvan.
ATE452683T1 (de) 3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3- methyl-5-oxo-4h-pyrazol-4-yliden hydrazino -2'- hydroxy- 1,1'-biphenyl -3-carbonsaure-bis- (monoethanolamin)
UY27863A1 (es) Nueva combinacion
HN2003000285A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
UY28007A1 (es) Tratamiento terapeutico
NO20075662L (no) Roflumilast for behandlingen av pulmonal hypertensjon
UY27816A1 (es) Nueva combinacion
DK1622908T3 (da) Xanthin-derivater som A2B adenosin-receptor-antagonister
ATE390425T1 (de) Xanthin-phosphodiesterase-v-hemmer polymorphe
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
SE0301654D0 (sv) Novel compounds
EA200401137A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
DOP2003000649A (es) Nueva combinacion
DE60219788D1 (de) Tetrazyklische verbindungen als pde5-inhibitoren
DOP2003000645A (es) Nueva combinacion
NO20044186L (no) Peptid-deformylaseinhibitorer
UY26893A1 (es) Combinación farmacéutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversión de la angiotensina i
GT200500236A (es) Nueva combinaciòn antiparasitaria de principios activos
AR052522A1 (es) Combinacion de un inhibidor selectivo de reabsorcion de noradrenalina y un inhibidor de tipo 5 de fosfodiesterasa
ES1053341Y (es) Mini-cepillo y abrillantador dental de un solo uso.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150430